Related Experiment Videos
[Basic and clinical studies of cefotiam in pediatric field (author's transl)]
Insights
Cefotiam (CTM) shows strong antibacterial activity against E. coli and K. pneumoniae, comparable to cefazolin against S. aureus. Clinical studies in pediatric infections demonstrated high efficacy (93.8%) with minimal side effects.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Antibacterial Agents
Background:
- Cefotiam (CTM) is a cephalosporin antibiotic.
- Pediatric infections require effective and safe antimicrobial agents.
Purpose of the Study:
- To evaluate the antibacterial activity, pharmacokinetics, and clinical efficacy of cefotiam (CTM) in pediatric infections.
Main Methods:
- In vitro antibacterial activity of CTM was compared to cefazolin (CEZ).
- Pharmacokinetic parameters were assessed after intravenous administration of CTM (20 mg/kg) via 30-minute or 1-hour infusions.
- Clinical efficacy was evaluated in 16 pediatric patients with various infections.
Main Results:
- CTM exhibited significantly greater activity against E. coli and K. pneumoniae than CEZ.
- Mean peak serum levels of CTM ranged from 41.4 to 44.8 mcg/ml, with half-lives between 0.62 and 1.15 hours.
- CTM achieved a 93.8% good or excellent clinical response rate in pediatric patients, with one case of rash observed.
Conclusions:
- Cefotiam demonstrates potent antibacterial activity and favorable pharmacokinetic properties for pediatric use.
- CTM is effective and well-tolerated in treating a range of pediatric infections.
Abstract:
The basic and clinical studies of cefotiam (CTM) in pediatric infections were carried out, and the following results were obtained: 1. The antibacterial activity of CTM against S. aureus was equal or slightly less than that of cefazolin (CEZ). Those of CTM against E. coli and K. pneumoniae were eight times more active than those of CEZ. 2. CTM 20 mg/kg was administered wither by 30 minutes or 1 hour intravenous drip infusion. The peak serum levels were obtained at the end of each drip infusion, with the mean peak levels being 44.8 and 41.4 mcg/ml respectively. The serum levels at 1.5 and 2 hours after drip infusion were 2.8 and 2.2 mcg/ml respectively, and at 3.5 and 4 hours after drip and 4 hours after drip infusion were 0.3 and 0.7 mcg/ml respectively. The half lives were 0.62 and 1.15 hours, respectively. The mean urinary excretion over 6 hours were 52.8% in ;the 30 minutes drip infusion group and 42.6% in the 1 hour drip infusion group. 3. Clinical efficacy was evaluated in sixteen cases suffering from tonsillitis (4 cases), pneumonia (4), bronchitis (2), cervical lymphadenitis (2), purulent meningitis (2), suppurative arthritis (1) and suspected sepsis (1). Good and excellent responses were obtained in 15 of 16 cases (93.8%). Bacteriological response in the form of eradication was noted in 4 of 6 cases. Side effect observed was rash in 1 case, and laboratory abnormalities were elevation of BUN in 1 case and elevation of GPT in 2 cases.